

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research  
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data  
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes  
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005  
NEWS 18 DEC 21 IPC search and display fields enhanced in CA/CAplus with the IPC reform  
NEWS 19 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2  
  
NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:12:42 ON 27 DEC 2005

=> file reg  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:12:47 ON 27 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6  
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10821793\Struc 1.str



chain nodes :  
6 7 8 9 10 11 12 18 19 20 21 22 23 24

Page 3


```
ring nodes :  
1 2 3 4 5 13 14 15 16 17  
chain bonds :  
5-6 6-7 6-21 7-8 8-9 9-10 9-22 10-11 11-12 12-13 12-23 17-18 18-19  
18-24 19-20  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 13-14 13-17 14-15 15-16 16-17  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 6-7 6-21 7-8 9-10 9-22 10-11 12-13 12-23 13-14  
13-17 14-15 15-16 16-17 18-19 18-24 19-20  
exact bonds :  
5-6 8-9 11-12 17-18
```

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS  
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS
```

L1 STRUCTURE UPLOADED

```
=> d  
L1 HAS NO ANSWERS  
L1 STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> l1  
SAMPLE SEARCH INITIATED 12:13:02 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE
```

```
100.0% PROCESSED 8 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**  
BATCH **COMPLETE**  
PROJECTED ITERATIONS: 8 TO 329  
PROJECTED ANSWERS: 0 TO 0
```

L2 0 SEA SSS SAM L1

```
=> l1 full  
FULL SEARCH INITIATED 12:13:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 169 TO ITERATE
```

100.0% PROCESSED      169 ITERATIONS  
 SEARCH TIME: 00.00.01

11 ANSWERS

L3            11 SEA SSS FUL L1

=&gt; file caplus medline

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	161.54

FILE 'CAPLUS' ENTERED AT 12:13:11 ON 27 DEC 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:13:11 ON 27 DEC 2005

=&gt; l3



L4            4 L3

=&gt; dup rem l4

PROCESSING COMPLETED FOR L4

L5            4 DUP REM L4 (0 DUPLICATES REMOVED)

=&gt; d abs ibib hitstr 1-4

L5        ANSWER 1 OF 4    CAPLUS    COPYRIGHT 2005 ACS on STN  
 GI


AB        The invention relates to compds. I [Ar is a 5- to 10-membered aromatic ring having up to 4 heteroatoms O, S, NH, SO and SO<sub>2</sub>, in which 1-3 ring atoms

are optionally substituted; R1, R2 are independently (un)substituted (hetero)alkyl, cycloalk(en)yl, cycloalk(en)yl-, aryl- or heteroaryl-(hetero)alkyl; R3, R3' are independently H, (un)substituted alkyl, halo-, sulfhydryl- or hydroxyalkyl, Ph or benzyl; or R3R3' is a ring; R4, R4' are independently H, (un)substituted (hetero)alkyl, cycloalkyl(hetero)alkyl, aryl or heterocycl; W is COCOR6, COCO2R6, COCONR62 (R6 is H, alkyl, (hetero)aryl, etc.) or a boryl group; T is alkyl, (hetero)aryl or (hetero)alkyl] that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The invention further relates to processes for preparing these compds. and to pharmaceutical compns. containing them. Thus, peptide II was prepared via peptide coupling reactions in solution and shown to have HCV NS3-NS4A protease inhibitory activity ( $K_i < 0.1 \mu\text{M}$  and  $\text{IC}_{50} < 0.5 \mu\text{M}$ ).



ACCESSION NUMBER: 2005:347009 CAPLUS  
 DOCUMENT NUMBER: 142:411657  
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease  
 INVENTOR(S): Perni, Robert B.; Court, John J.; Britt, Shawn D.; Pitlik, Janos; Van Drie, John H.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 150 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035525	A2	20050421	WO 2004-US29093	20040907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005137139	A1	20050623	US 2004-936450	20040907
PRIORITY APPLN. INFO.:			US 2003-500670P	P 20030905
OTHER SOURCE(S):	MARPAT 142:411657			
IT 850251-11-5P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)			
RN 850251-11-5	CAPLUS			
CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-4-(1-naphthalenylxy)-(4R)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
GI



AB The invention relates to compds. I [the R groups are H (except R1, R3) or various groups, i.e., R5, R5' are alkyl, halo-, mercapto- or hydroxyalkyl, (un)substituted Ph or benzyl or R5/R5' may form a ring; R2, R4, R7 are (un)substituted alkyl, cycloalkylalkyl or arylalkyl; R1, R3 are (un)substituted alkyl, cycloalkyl, cycloalkylalkyl, etc.; R9, R9', R10, R10' are -X-Y-Z, where X is a bond, alkylene, O, S or imino, Y is a bond, CH<sub>2</sub>, CO, COCO, SO, SO<sub>2</sub> or sulfinylimino, Z is H, alkyl, aryl, etc.; V is CO, SO or SO<sub>2</sub>, R is CO, SO, SO<sub>2</sub>, imino, O or a bond; T is alkyl, aryl, etc; W is an acyl or boryl group] or their pharmaceutically-acceptable salts that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Thus, peptide II was prepared by


peptide coupling reactions in solution and showed Ki in the range 0.5-1  $\mu\text{M}$  for inhibition of HCV.

ACCESSION NUMBER: 2004:902372 CAPLUS  
 DOCUMENT NUMBER: 141:350404  
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease  
 INVENTOR(S): Farmer, Luc J.; Perni, Robert P.; Bhise, Govinda Rao; Wilson, Keith P.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA  
 SOURCE: PCT Int. Appl., 116 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092162	A1	20041028	WO 2004-US11012	20040409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004018986	A1	20040129	US 2003-412600	20030411
CA 2521678	AA	20041028	CA 2004-2521678	20040409
US 2005090450	A1	20050428	US 2004-821793	20040409
PRIORITY APPLN. INFO.:			US 2003-412600	A 20030411
			US 2003-513765P	P 20031023
			US 2002-371846P	P 20020411
			WO 2004-US11012	W 20040409


OTHER SOURCE(S): MARPAT 141:350404  
 IT 777087-23-7P 777087-37-3P 777087-38-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)  
 RN 777087-23-7 CAPLUS  
 CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-L-valyl-N-[1-[(cyclopropylamino)oxoacetyl]butyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777087-37-3 CAPLUS  
CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-3-cyclohexyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777087-38-4 CAPLUS  
CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-3-(1-methylethyl)-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AB The invention discloses peptidomimetic compds. which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compds. of the invention have a bridged bicyclic moiety at the P2 position. The invention further discloses compns. comprising these compds., either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also discloses methods of treating an HCV infection in a patient by administering a composition comprising a compound of the invention. Preparation of compds. of the invention is described.

ACCESSION NUMBER: 2003:58112 CAPLUS  
DOCUMENT NUMBER: 138:117634  
TITLE: Bridged bicyclic peptidomimetic serine protease inhibitors, and use as antiviral agents against hepatitis C virus  
INVENTOR(S): Farmer, Luc; Pitlik, Janos; Perni, Robert; Courtney, Lawrence; Van Drie, John

PATENT ASSIGNEE(S) : Vertex Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006490	A1	20030123	WO 2002-US22027	20020711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2449504	AA	20030123	CA 2002-2449504	20020711
US 2003119752	A1	20030626	US 2002-193048	20020711
US 6909000	B2	20050621		
EP 1404704	A1	20040407	EP 2002-749965	20020711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE				
CN 1525979	A	20040901	CN 2002-813816	20020711
JP 2005522409	T2	20050728	JP 2003-512260	20020711
ZA 2003009156	A	20050527	ZA 2003-9156	20031125
NO 2004000127	A	20040311	NO 2004-127	20040112
PRIORITY APPLN. INFO.:			US 2001-304615P	P 20010711
			US 2001-322714P	P 20010917
			WO 2002-US22027	W 20020711


OTHER SOURCE(S) : MARPAT 138:117634

IT 488781-08-4 488781-09-5  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (bridged bicyclic peptidomimetic serine protease inhibitors, and use as  
 antiviral agents against hepatitis C virus)

RN 488781-08-4 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-  
 cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[oxo[[1S]-1-  
 phenylethyl]amino]acetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488781-09-5 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
GI



AB Peptidomimetic compds. R9-L-(NR8-R7-CO)nNR6-R5-CO-NX-CONR4-R3-CO-R-CONR1R2  
[R is a bond or CF<sub>2</sub>; R1 is H, (un)substituted an aliphatic, cyclic, or aromatic group; R2, R9 are (un)substituted aliphatic, cyclic, or aromatic groups; R3, R5,  
R7 are (un)substituted 1,1- or 1,2-cycloalkylene or -heterocyclylene, methylene or ethylene; R4, R6, R8 and R10 are H or an optionally substituted aliphatic group; NX is an (un)substituted cyclic azaheterocycl or azaheterocyclenyl having the unsatn. in the ring distal to ring bearing the -R5-C(O)-N moiety and to which the -CONR4- moiety is attached; L is CO, O<sub>2</sub>C, NR<sub>10</sub>CO, SO<sub>2</sub>, or NR<sub>10</sub>SO<sub>2</sub>; n is 0 or 1] or pharmaceutically acceptable salts or prodrugs were prepared for use as protease inhibitors, particularly as hepatitis C NS3 protease inhibitors. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compds. having anti HCV activity and a pharmaceutically acceptable carrier. Thus, compd I was prepared and assayed for HCV serine protease inhibitory activity in combination with interferons. When used as a single drug treatment, I exhibits an IC<sub>50</sub> of 0.48 μM and interferon-α 2B is 2.19 U.

ACCESSION NUMBER: 2002:171885 CAPLUS

DOCUMENT NUMBER: 136:232547

TITLE: Preparation of peptidomimetic protease inhibitors

INVENTOR(S): Babine, Robert Edward; Chen, Shu Hui; Lamar, Jason Eric; Snyder, Nancy June; Sun, Xicheng David; Tebbe, Mark Joseph; Victor, Frantz; Wang, Q. May; Yip, Yvonne Yee Mai; Collado, Ivan; Garcia-Paredes, Cristina; Parker, Raymond Samuel, III; Jin, Ling; Guo, Deqi; Glass, John Irvin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 424 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018369	A2	20020307	WO 2001-US26008	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,				

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2419607 AA 20020307 CA 2001-2419607 20010831  
 AU 2001088318 A5 20020313 AU 2001-88318 20010831  
 EP 1320540 A2 20030625 EP 2001-968040 20010831  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004517047 T2 20040610 JP 2002-523884 20010831  
 BR 2001013666 A 20050927 BR 2001-13666 20010831  
 NO 2003000928 A 20030416 NO 2003-928 20030227  
 ZA 2003001641 A 20040621 ZA 2003-1641 20030227  
 US 2005197299 A1 20050908 US 2004-344112 20041217  
 PRIORITY APPLN. INFO.: US 2000-229398P P 20000831  
 US 2001-277641P P 20010321  
 WO 2001-US26008 W 20010831

OTHER SOURCE(S): MARPAT 136:232547

IT 402957-63-5P 402957-89-5P 402957-90-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidomimetic protease inhibitors)

RN 402957-63-5 CAPPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402957-89-5 CAPPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-methyl-1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402957-90-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 402960-13-8P 402960-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of peptidomimetic protease inhibitors)

RN 402960-13-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-(phenylmethyl)-1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402960-14-9 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; log h

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

27.49

189.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-2.92

-2.92

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:23:40 ON 27 DEC 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626